Symphogen CEO Drejer to step down

Symphogen said Aug. 18 that CEO Kirsten Drejer is stepping down and will become an independent member of the Board. Martin Olin, current Symphogen CFO, will become CEO effective Sept. 1. Copenhagen-based Symphogen, a biopharmaceutical company, is backed by investors including Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures Inc and Genentech.

PeopleNorth AmericaUSBriefs